Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib vs Erlotinib in KRAS-mutant NSCLC
NCT02152631Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2014
- Primary completion
- Sep 2017
- Countries
- 21
01
Overview
A Phase 3 trial of abemaciclib in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Oct 2014; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02152631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02152631.